Presentations and PublicationsRead about publications and presentations made by Benitec's scientific team below. For details of Benitec's announcements to the ASX, read details in our Investor Centre.
Significant Enhancement of Hepatitis B Virus (HBV) Suppression with Standard of Care Drugs Following Co-Administration of a DNA-Directed RNA Interference Agent in a Chimeric Mouse Model 24 MAY 2017
Superior suppression of Hepatitis B virus (HBV) DNA and antigen levels in a chimeric mouse model when BB-103, a DNA-Directed RNA interference (ddRNAi) agent, is coupled with standard of care drugs 19 APR 2017
BB-HB-331, a DNA-Directed RNA Interference Agent, Suppresses Hepatitis B virus (HBV) in vitro and in vivo 18 OCT 2016
Toxicology evaluation of TT-034 demonstrates durable expression in hepatic tissues without long term adverse effects on endogenous miRNA levels 5 MAY 2016
A comparison of scAAV8-TT034 mediated transduction and shRNA expression in human liver biopsy samples versus a chimeric mouse model with humanized liver 5 MAY 2016
BB-HB-331, a DNA-Directed RNA Interference (ddRNAi) Agent Targeting Hepatitis B Virus (HBV), Can Effectively Suppress HBV In Vitro and In Vivo 5 MAY 2016
Phase I/IIa study of TT-034, a DNA-directed RNA interference agent (ddRNAi) delivered as a single administration for the treatment of subjects with chronic hepatitis C virus (HCV) 14 NOV 2015